α-Synuclein: membrane interactions and toxicity in Parkinson's disease.

In the late 1990s, mutations in the synaptic protein α-synuclein (α-syn) were identified in families with hereditary Parkinson's disease (PD). Rapidly, α-syn became the target of numerous investigations that have transformed our understanding of the pathogenesis underlying this disorder. α-Syn is the major component of Lewy bodies (LBs), cytoplasmic protein aggregates that form in the neurons of PD patients. α-Syn interacts with lipid membranes and adopts amyloid conformations that deposit within LBs. Work in yeast and other model systems has revealed that α-syn-associated toxicity might be the consequence of abnormal membrane interactions and alterations in vesicle trafficking. Here we review evidence regarding α-syn's normal interactions with membranes and regulation of synaptic vesicles as well as how overexpression of α-syn yields global cellular dysfunction. Finally, we present a model linking vesicle dynamics to toxicity with the sincere hope that understanding these disease mechanisms will lead to the development of novel, potent therapeutics.

[1]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  Clare M Waterman,et al.  Mechanical integration of actin and adhesion dynamics in cell migration. , 2010, Annual review of cell and developmental biology.

[3]  C. Desplan,et al.  Stochastic mechanisms of cell fate specification that yield random or robust outcomes. , 2010, Annual review of cell and developmental biology.

[4]  W. Wickner Membrane fusion: five lipids, four SNAREs, three chaperones, two nucleotides, and a Rab, all dancing in a ring on yeast vacuoles. , 2010, Annual review of cell and developmental biology.

[5]  Peter McCourt,et al.  Plant nuclear hormone receptors: a role for small molecules in protein-protein interactions. , 2010, Annual review of cell and developmental biology.

[6]  Frederick Grinnell,et al.  Cell motility and mechanics in three-dimensional collagen matrices. , 2010, Annual review of cell and developmental biology.

[7]  Heidi N. Fridolfsson,et al.  Interactions between nuclei and the cytoskeleton are mediated by SUN-KASH nuclear-envelope bridges. , 2010, Annual review of cell and developmental biology.

[8]  J. Hay,et al.  α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs , 2010, Molecular biology of the cell.

[9]  Joshua A. Kritzer,et al.  Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models , 2010, Disease Models & Mechanisms.

[10]  Kwang-Soo Kim,et al.  LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. , 2010, Experimental cell research.

[11]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[12]  O. Isacson,et al.  Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression , 2009, Proceedings of the National Academy of Sciences.

[13]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[14]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[15]  A. Nohturfft,et al.  Coordination of lipid metabolism in membrane biogenesis. , 2009, Annual review of cell and developmental biology.

[16]  Tatiana Foroud,et al.  Genomewide association study for onset age in Parkinson disease , 2009, BMC Medical Genetics.

[17]  R. Cappai,et al.  The Molecular Chaperone Hsp90 Modulates Intermediate Steps of Amyloid Assembly of the Parkinson-related Protein α-Synuclein* , 2009, The Journal of Biological Chemistry.

[18]  Connie Marras,et al.  Occupation and risk of parkinsonism: a multicenter case-control study. , 2009, Archives of neurology.

[19]  H. Stenmark Rab GTPases as coordinators of vesicle traffic , 2009, Nature Reviews Molecular Cell Biology.

[20]  Aj Lees,et al.  Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .

[21]  Peter Walter,et al.  Supporting Online Material for An ER-Mitochondria Tethering Complex Revealed by a Synthetic Biology Screen , 2009 .

[22]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[23]  M. Kreft,et al.  Sphingosine Facilitates SNARE Complex Assembly and Activates Synaptic Vesicle Exocytosis , 2009, Neuron.

[24]  H. Lashuel,et al.  E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.

[25]  Victor Tapias,et al.  A highly reproducible rotenone model of Parkinson's disease , 2009, Neurobiology of Disease.

[26]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[27]  M. Stampfer Welding Occupations and Mortality from Parkinson's Disease and Other Neurodegenerative Diseases Among United States Men, 1985–1999 , 2009, Journal of occupational and environmental hygiene.

[28]  M. Hasegawa,et al.  Conversion of Wild-type α-Synuclein into Mutant-type Fibrils and Its Propagation in the Presence of A30P Mutant* , 2009, Journal of Biological Chemistry.

[29]  Jason D. Perlmutter,et al.  Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. , 2009, The Journal of biological chemistry.

[30]  D. Karger,et al.  Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity , 2009, Nature Genetics.

[31]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[32]  L. Scorrano,et al.  Mitofusin 2 tethers endoplasmic reticulum to mitochondria , 2008, Nature.

[33]  A. Ariza,et al.  The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. , 2008, Current medicinal chemistry.

[34]  T. Iwatsubo,et al.  A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. , 2008, Human molecular genetics.

[35]  A. Elbaz,et al.  Update in the epidemiology of Parkinson's disease , 2008, Current opinion in neurology.

[36]  P. Emson,et al.  Altered vesicular dopamine storage in Parkinson's disease: a premature demise , 2008, Trends in Neurosciences.

[37]  Xuemei Huang,et al.  Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[38]  M. Ripoli,et al.  Mitochondrial Respiratory Dysfunction in Familiar Parkinsonism Associated with PINK1 Mutation , 2008, Neurochemical Research.

[39]  F. Giorgini,et al.  Yeast as a model for studying human neurodegenerative disorders , 2008, Biotechnology journal.

[40]  Sonja W. Scholz,et al.  Genomewide SNP assay reveals mutations underlying Parkinson disease , 2008, Human mutation.

[41]  S. Lindquist,et al.  The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis , 2008, Proceedings of the National Academy of Sciences.

[42]  J. Trojanowski,et al.  Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. , 2007, Molecular biology of the cell.

[43]  Koichi Abe,et al.  Peptide ligand screening of α-synuclein aggregation modulators by in silico panning , 2007, BMC Bioinformatics.

[44]  Kara Dolinski,et al.  Gene Ontology annotations at SGD: new data sources and annotation methods , 2007, Nucleic Acids Res..

[45]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[46]  D. Perl,et al.  The Neuropathology of Manganese-Induced Parkinsonism , 2007, Journal of neuropathology and experimental neurology.

[47]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[48]  B. Davletov,et al.  Regulation of SNARE fusion machinery by fatty acids , 2007, Cellular and Molecular Life Sciences.

[49]  M. Feany,et al.  Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo , 2007, The Journal of Neuroscience.

[50]  J. Trojanowski,et al.  Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model , 2007 .

[51]  N. Scott,et al.  Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study , 2007, Occupational and Environmental Medicine.

[52]  Kevin R. Sanft,et al.  Chemical exposures and Parkinson's disease: A population‐based case–control study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[53]  Kexiang Xu,et al.  Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging , 2006, Proceedings of the National Academy of Sciences.

[54]  W. Balch,et al.  The Hsp90 chaperone complex regulates GDI-dependent Rab recycling. , 2006, Molecular biology of the cell.

[55]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[56]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[57]  R. Nass,et al.  Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein , 2006, Neurobiology of Disease.

[58]  F. Kamp,et al.  Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.

[59]  F. Giorgini,et al.  Yeast as a drug discovery platform in Huntington's and Parkinson's diseases , 2006, Biotechnology journal.

[60]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[61]  M. Beal,et al.  Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. A. Froelich,et al.  Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. , 2005, Journal of molecular biology.

[63]  P. Auluck,et al.  Mechanisms of Suppression of α-Synuclein Neurotoxicity by Geldanamycin in Drosophila* , 2005, Journal of Biological Chemistry.

[64]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[65]  J. Allman,et al.  Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.

[66]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[67]  G. Mardon,et al.  Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.

[68]  T. Gómez-Isla,et al.  Abnormal α‐Synuclein Interactions with Rab Proteins in α‐Synuclein A30P Transgenic Mice , 2004 .

[69]  Diego Guidolin,et al.  α‐Synuclein and Parkinson's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  T. Gómez-Isla,et al.  Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. , 2004, Journal of neuropathology and experimental neurology.

[71]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[72]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[73]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[74]  Clemens R Scherzer,et al.  Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. , 2003, Human molecular genetics.

[75]  B. Giasson,et al.  Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.

[76]  R. Blakely,et al.  Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.

[77]  David W. Miller,et al.  Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.

[78]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[79]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[80]  W. Balch,et al.  Rab‐αGDI activity is regulated by a Hsp90 chaperone complex , 2002 .

[81]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[82]  Nutan Sharma,et al.  TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.

[83]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[84]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[86]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[87]  R. Perrin,et al.  Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.

[88]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[89]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[90]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[91]  A. Brice,et al.  Alpha-synuclein and Parkinson's disease , 2000, Cellular and Molecular Life Sciences CMLS.

[92]  P. S. St George-Hyslop,et al.  α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.

[93]  R. Perrin,et al.  Interaction of Human α-Synuclein and Parkinson's Disease Variants with Phospholipids , 2000, The Journal of Biological Chemistry.

[94]  M. Citron,et al.  Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs* , 2000, The Journal of Biological Chemistry.

[95]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[96]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[97]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[98]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[99]  N. Taylor,et al.  Could mitochondrial dysfunction play a role in manganese toxicity? , 1999, Environmental toxicology and pharmacology.

[100]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[101]  C. Lavedan The synuclein family. , 1998, Genome research.

[102]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[103]  Makoto Hashimoto,et al.  Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.

[104]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[105]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[106]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[107]  J. Vance,et al.  Import of lipids into mitochondria. , 1997, Progress in lipid research.

[108]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[109]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[110]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[111]  M. Kozlov,et al.  Lipids in biological membrane fusion , 1995, The Journal of Membrane Biology.

[112]  H. Przuntek,et al.  Increased Risk of Parkinson's Disease in Relatives of Patients , 1995, Annals of neurology.

[113]  J. Kimura,et al.  Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains , 1994, Brain Research.

[114]  G. Anantharamaiah,et al.  The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. , 1992, Journal of lipid research.

[115]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[116]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[117]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[118]  L T Smyth,et al.  Clinical manganism and exposure to manganese in the production and processing of ferromanganese alloy. , 1973, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[119]  P. Mueller,et al.  Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa , 1971, Clinical pharmacology and therapeutics.

[120]  W. A. Jager,et al.  Sphingomyelin in Lewy inclusion bodies in Parkinson's disease. , 1969 .

[121]  A. Destée,et al.  Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. , 2009, Archives of neurology.

[122]  H. Lashuel,et al.  E 46 K Parkinson ’ sLinked Mutation Enhances C-Terminal-toN-Terminal Contacts in α-Synuclein , 2009 .

[123]  J. Cano,et al.  Mitochondrial toxins and neurodegenerative diseases. , 2007, Frontiers in bioscience : a journal and virtual library.

[124]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[125]  H De Loof,et al.  Amphipathic helix motif: Classes and properties , 1990, Proteins.

[126]  P. Riekkinen,et al.  Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. , 1975, Archives of neurology.